Article Figures & Data
Figures
- Figure 1.
A, Western blot showing EGFR, HER-2, and HER-4 levels in different colon (HT-29, HCT-116, and Caco2) and breast (MDA-468 and SKBR-3) cell lines, and nontransformed rat small intestinal cell line IEC-6. Each lane contained 25 μg protein. B, effect of increasing concentrations of recombinant ERRP on the growth [determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay] of colon and breast cancer cell lines as well as on cell lines derived from fibroblasts (NIH-3T3 and NIH-3T3/PT-67) and nontransformed rat small intestine (IEC-6). Points, mean of six to seven independent determinations; bars, SE.
- Figure 2.
Effects of increasing concentrations of recombinant ERRP, cetuximab (A), or trastuzumab (B) on the growth of colon (HCT-116 and HT-29) and breast (MDA-468 and SKBR-3) cancer cell lines. Cells were exposed to recombinant ERRP, cetuximab, or trastuzumab for 48 h. Points, mean of six to seven determinations; bars, SE. *P < 0.01, compared with the corresponding values of cetuximab- or trastuzumab-treated cells.
- Figure 3.
Attenuation of TGF-α (T) and HB-EGF (HB) induced tyrosine phosphorylation of EGFR (p-EGFR; A) and Her-2 (p-Her2;; B) in the presence of recombinant ERRP, cetuximab (Cetux), or tarstuzumab (Trast) in colon (HCT-116 and HT-29) and breast (MDA-468 and SKBR-3) cancer cells. Actin served as the loading control.
- Figure 4.
Attenuation of heregulin-α–induced tyrosine phosphorylation of HER-2 (p-HER2) in the presence of recombinant ERRP, cetuximab (Cetux), or tarstuzumab (Trast) in colon (HT-29) and breast (SKBR-3) cancer cells. α-Tubulin served as the loading control.
- Figure 5.
Effects of recombinant ERRP, cetuximab, or trastuzumab on apoptosis of colon (HCT-116 and HT-29) and breast (MDA-468 and SKBR-3) cancer cells as well as the mouse fibroblast (NIH-3T3) and nontransformed rat small intestinal IEC-6 cells. Cells were exposed to recombinant ERRP, cetuximab, or trastuzumab for 24 h. Columns, mean of four to five determinations; bars, SE. *P < 0.01, compared with the corresponding controls.
Volume 4, Issue 3
